Podcasts about Dairy

Ted is a first generation farmer who started and built a large scale grazing based dairy that allows him to compete in an industry typically dominated by high capital production focused dairy farms. We discuss his start, the decision to get into this model, using virtual fence in a dairy context and so much more.Resources mentioned:National Grazing Lands CoalitionGraze MagazineRanching for ProfitGrazing Grass PodcastBusiness of Agriculture PodcastCheck out ⁠⁠⁠⁠⁠⁠www.pharocattle.com⁠⁠⁠⁠⁠⁠ for more information on how to put more fun and profit back into your ranching business! As always, check us out at Ranching Returns Podcast on Facebook and Instagram as well as at ⁠www.ranchingreturns.com⁠.For Ranching Returns shirts, hats, and sweatshirts check out https://farmfocused.com/ranching-returns-merch/If you're interested in Farmatan to fight scours in your operation, call Paul Mitchell at 515-745-1639 or check out farmatanusa.com.To learn more about all the classes and services that Noble offers check out www.noble.org

12-19-25 - Guad Squares - w/Frank Caliendo - Biden - Alec Baldwin - Jay Leno - Morgan Morgan And Morgan - Dairy Dreamer Brady - Barkley And Shaq - 01-20-23 - BOSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

12-19-25 - Guad Squares - w/Frank Caliendo - Biden - Alec Baldwin - Jay Leno - Morgan Morgan And Morgan - Dairy Dreamer Brady - Barkley And Shaq - 01-20-23 - BOSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In this episode of the Uplevel Dairy Podcast, Peggy Coffeen talks with Curtis Bosma from HighGround Dairy about the current state of the dairy market as of December 2025 and projections for 2026. They discuss stagnant dairy prices, particularly in cheese and butter, the role of whey in sustaining Class 3 milk prices, and the impacts of overproduction and bird flu on milk supply. Curtis also provides insights into alternative revenue sources like beef streams and methane digesters that are supporting dairy farmers. The episode closes with strategic advice for dairy producers to manage margins and plan ahead for the new year.Grab your own copy of the monthly market update here: https://marketing.highgrounddairy.com/december-2025-producer-market-updateThis episode is brought to you by: HighGround Dairy provides global dairy market intelligence, insurance services, futures & options brokerage, and advisory programs to a diverse range of dairy market participants throughout the supply chain.00:00 Introduction to Dairy Market Trends00:42 Current Dairy Market Overview03:07 Milk Production Insights04:39 Bird Flu Impact on Dairy Market07:58 Cheese and Butter Market Analysis11:51 Whey Protein: The Unsung Hero13:08 Alternative Revenue Sources for Dairy Farms16:32 Strategies for 202621:06 Final ThoughtsInformation shared in this podcast is for educational purposes and is not a solicitation to buy or sell commodities.  Opinions expressed are current opinions as of December 17, 2025 at 1  p.m. CST and only represent the views of the speaker and not those of HighGround Trading, unless otherwise expressly noted.

Dairy bread?

The holiday push is wrapping up, and the markets are starting to show their hand. Beef is splitting in two directions, poultry feels steady but uneasy, pork stays a value, grains won't budge, and dairy may finally be finding a floor. With January right around the corner, the next two weeks could set the tone for everything that follows.BEEF: Holiday pricing is making its final stand, and the beef market is starting to split in two directions. Middle meats are finally easing while other cuts quietly set up their next move. Two weeks from now, this market could look very different.POULTRY: Chicken finishes the year well supplied and steady, but this calm feels temporary. With avian flu still popping up and no real downside left, the next move is likely up – the only question is when.GRAINS: Soy export news finally surfaced, but the grain markets barely blinked. Corn, soy, and wheat remain stuck in neutral, waiting for something – anything – to break the stalemate.PORK: Bellies slide again, keeping bacon firmly in value territory heading into the new year. With strong production and solid inventories, pork remains one of the quiet winners on the board.DAIRY: Dairy prices are sending mixed signals, hinting the recent slide may be running out of steam. Whether this is the bottom or just another pause is the next story to watch.Savalfoods.com | Find us on Social Media: Instagram, Facebook, YouTube, Twitter, LinkedIn

"Seven with Kevin" featuring Illinois Farm Bureau Executive Director of Governmental Affairs and Commodities Kevin Semlow. Illinois Ag Leadership Class of 2027 update.IHSA Friday Friday Friday segment features WRMJ Sports Director Ty Taylor discussing IHSA football playoff expansion proposal that won approval this week.  

Greg Brady spoke with Dr. Sylvain Charlebois, “The Food Professor”, Senior Director of the AGRI-FOOD ANALYTICS LAB at Dalhousie University about Supply management 'not on the table,' says Carney as U.S. bent on changing dairy rules. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode of The Line Podcast, hosts Jen Gerson and Andrew Potter discuss trade, immigration, and the attempts to "Globalize the Intifada." Firstly, on the trade file, US trade rep Jamieson Greer has issued a list of grievances. The Americans are villainously committed to giving Canadians more options for eggs, chicken, and dairy. StatsCan shows a dramatic drop in immigration as the LIberals reign in a system gone pear shaped. And lastly, what do the young think "Globalize the Intifada" really means? 

Greg Brady spoke with Dr. Sylvain Charlebois, “The Food Professor”, Senior Director of the AGRI-FOOD ANALYTICS LAB at Dalhousie University about Supply management 'not on the table,' says Carney as U.S. bent on changing dairy rules. Learn more about your ad choices. Visit megaphone.fm/adchoices

Agricultural nutrient and waste management discoveries.

Lumpy Skin Disease continues to spread in Europe, Bluetongue was recently found in Northern Ireland for the first time and bird flu was found in dairy cows for the first time in Wisconsin. Could these diseases suddenly slow milk production growth faster than the market is expecting?

For this week's episode of the Dairy Edge, in conjunction with Catherine Egan of the Beef Edge and Ciaran Lynch of OviCast, we talk to John Donlon, veterinary lecturer in Atlantic Technological University about bluetongue. John first describes the disease and explains how it presents in sheep, cattle, alpacas and other cloven hooved animals. He then explains how, in reality, the risk period should have passed at this stage of the year as midges that act as the vector for the disease should be gone by now. The cold weather is a help in that midge activity will be reduced or eliminated but that doesn't mean the risk isn't still there. People must remain vigilant and notify their vet and relevant authorities in the event of suspecting an animal has bluetongue. Trading implications could exist were a case to be identified in the Republic which would have ramifications for livestock movements, but currently there are no restrictions as the country is still bluetongue free. If a case were to be discovered, vaccines are available to reduce the severity of the disease but one would have to get an emergency license from the Department of Agriculture. Careful monitoring of stock for any signs are advised and swift notification, if identified, to facilitate rapid control is advised. For more episodes from the Dairy Edge podcast go to the show page at:https://www.teagasc.ie/animals/dairy/the-dairy-edge-podcast/ The Dairy Edge is a co-production with LastCastMedia.com

It's a big day in Washington D.C for wolves. The House of Representatives will vote on the Pet and Livestock Protection Act. Ultimately, the decision will determine if the gray wolf will stay on the endangered species list. Fabulous Farm Babe Pam Jahnke and Wisconsin DNR Large Carnivore Specialist, Randy Johnson, discuss Wisconsin's wolf population data and movement patterns. Ag meteorologist Stu Muck and Kiley Allan talk about the warmer temperatures we have been seeing. Temperatures will continue to swing in the upcoming week. No two days as a veterinarian look the same. Dr. Monty Belmer, a local veterinarian explains the standard practices and the heightened precautions veterinarians take when a disease outbreak occurs to Stephanie Hoff. Dr. Arden Anderson, a Physician and Agricultural Consultant, tells Ben Jarboe that farmers are a high-risk group for several health concerns including cancer, heart disease, and Parkinson’s disease. He tells us one reason why the group is considered high risk.Dairy market analyst, Cody Koster, breaks down the suspected market effects of Avian Influenza. He looks into his crystal ball and forecasts the GDT trends we can expect going into the new year.See omnystudio.com/listener for privacy information.

In this episode of The Dairy Nutrition Blackbelt Podcast, Dr. Javier Alba Mayagoitia from Priority IAC explains how microbial-driven nutrition can stabilize rumen function and support healthier, more efficient dairy cows. He covers targeted strains, rumen fermentation challenges, and practical feeding principles producers can apply on-farm. Learn how microbiology connects with nutrition to strengthen performance. Listen now on all major platforms."Smartbacteria is a concept that includes strains with specific functions for digestion, disease prevention, and cow health."Meet the guest: Dr. Javier Alba Mayagoitia is a veterinary microbiology nutritionist and Director of Priority IAC México. With 32 years in dairy and beef cattle practice across mastitis, herd management, and nutrition, he now focuses on microbiology-based feeding strategies. Liked this one? Don't stop now — Here's what we think you'll love!What will you learn: (00:00) Highlight(01:21) Introduction(05:01) Smartbacteria explained(06:21) Preventing acidosis(08:09) Nutrition principles(10:07) Feed management tips(11:26) Protein efficiency(14:15) Closing thoughtsThe Dairy Nutrition Blackbelt Podcast is trusted and supported by the innovative companies:* Priority IAC* Fortiva* Adisseo- Kemin- Virtus Nutrition

Bill Graff, State Executive Director for the USDA Farm Service Agency in Illinois discusses the Farmer Bridge Assistance Program.   Raghela Scavuzzo, Illinois Farm Bureau Associate Director of Food Systems Development highlights the "specialtygrowers.org/shoplocal" online resource. Updates from the American Farmland Trust and Illinois Wheat Association.   

Dairy farmer and agribusiness leader Nathan Guy is New Zealand's new special agricultural trade envoy. Todd McClay, Minister for Trade and Investment and Minister of Agriculture, announced Guy's appointment today. The Country's Jamie Mackay explains further. LISTEN ABOVESee omnystudio.com/listener for privacy information.

We know how important it is to be inspired by both big businesses and individuals, which is why we are excited to present Talking Leaders, a monthly initiative from the AHDB which will see a series of inspirational speakers share their life experiences and deliver impactful stories to the AgriLeader community.In the December episode of Talking Leaders, we were delighted to be joined by Hattie McFadzean, Senior Consultant at Promar International and recent Nuffield Farming Scholar. With weather patterns becoming increasingly unpredictable, how can UK dairy farmers build resilience and adapt for the future? Hattie joins us to discuss the findings of her Nuffield study, “Enhancing the Resilience of the UK Dairy Sector: How Do We Practically Adapt to Increasingly Volatile Weather Conditions?”Drawing on insights from her travels and research, Hattie explores how dairy businesses around the world are responding to climate variability and what practical steps UK producers can take to “weather-proof” their own operations.Hear Hattie's reflections on leadership, innovation, and collaboration across the dairy sector – and how embracing change today can help secure a more sustainable future for tomorrow's farmers.

Dairy farmer and agribusiness leader Nathan Guy is New Zealand's new special agricultural trade envoy. Todd McClay, Minister for Trade and Investment and Minister of Agriculture, announced Guy's appointment today. The Country's Jamie Mackay explains further. LISTEN ABOVESee omnystudio.com/listener for privacy information.

We were fortunate enough, for this episode, to be joined by Austin Koch of Earth Optics, to discuss a more prescriptive approach to soil health. A great listen you won't want to miss!

California awards $6.3 million to support manure management and dairy digester projects on livestock farms statewide.

Talking urban agriculture at Augustana College in Rock Island with Ian Empen and the "Augie Acres" project. AAA's Molly Hart discusses holiday travel numbers.  Monthly update from Illinois Farm Bureau Associate Director of Transportation and Infrastructure Rodney Knittel.  

What began as a childhood 4-H project has grown into a thriving value-added dairy business feeding families across New England.This week on American Family Farmer, host Doug Stephan welcomes sisters Beth and Courtney Hodge, co-owners of Echo Farm Puddings in Hinsdale, New Hampshire. Raised on a small farm, the Hodge sisters turned their love for cows—and their reluctance to part with them—into a creative solution that helped sustain their family dairy through volatile milk markets and industry challenges.Beth manages the dairy herd while Courtney oversees pudding production, but their work overlaps daily as they balance farming, manufacturing, and marketing. About 20% of their milk is transformed into small-batch pudding made entirely on-farm, while the rest goes into the Cabot cheese supply chain. That modest percentage of milk, however, generates a disproportionately large share of the farm's revenue—proving how powerful value-added agriculture can be for family farms.The conversation covers how a garage-based 4-H project evolved into a regional pudding brand, why pudding became a “farm-saver” during tough times for dairy, what it really takes to run on-farm food manufacturing, how Certified Humane practices helped them stand out and reach new markets, the role of sustainability, from feeding spent brewery grain to partnering with local farmers, and why loving the act of feeding people is at the heart of everything they do.This episode is a must-listen for farmers exploring diversification, consumers curious about where their food comes from, and anyone inspired by family-run businesses that adapt, innovate, and endure.Visit them at EchoFarmPuddings.com and Like them on Facebook. Website: AmericanFamilyFarmerShow.com Social Media: @GoodDayNetworks

Eve gives an overview of current and future consumer trends where dairy can play a role. Functional foods, health and wellness, high protein foods, fermented and cultured foods, women's health, brain health, and aging are all part of the mix. (7:26)The panelists discuss the healthfulness of saturated fats, the resurgence of butter, milk's bioactive compounds, and how best to reach the public about the health benefits of dairy. (10:41)Eve talks about marketing to Gen Z consumers, who are motivated by novelty. How do we reimagine a food that's been here for thousands of years? What new ways can we talk about it? What ways can we optimize dairy science and research to show up in generative systems like ChatGPT? (20:34)The group then tackles the topic of lactose. Lactose and honey are the only two sugars not made by plants. Why is it lactose that is in the milk of mammals? Dr. Jiminez-Flores thinks lactose is a dark horse in dairy and we have much yet to discover about it. He notes that some milk oligosaccharides are not digested by babies, but are used by bacteria in the development of a healthy microbiome. Dr. Lucy notes that dairy also contains peptides that have been found to reduce hypertension. The group also delves into how dairy products can be part of preventative health care. (23:53)Do consumers perceive dairy products to be minimally processed? Eve explains that dairy is perceived as a clean, fresh food. Given the current trend to reduce additives and food dyes, she sees potential for dairy food science innovation in this area. Dr. Aldrich talks about the glycemic index of lactose-free milk. (38:13)The panelists agree that dairy has a great upcycling story to tell. Converting fiber into milk and meat and feeding non-human grade byproducts are just two examples. Eve notes that younger consumers care about sustainability, but there's a huge “say-do” gap: 76% of North American consumers identify as caring about conscious and sustainable practices, but less than 40% actually act on those values when making purchases. The panel also notes that whey is another great upcycling story. Dr. Jiminez-Flores emphasizes how important consumer trust in science and research is, and how we are currently experiencing a loss of that trust. (45:48)Panelists share their take-home thoughts. (1:01:01)Please subscribe and share with your industry friends to invite more people to join us at the Real Science Exchange virtual pub table.  If you want one of our Real Science Exchange t-shirts, screenshot your rating, review, or subscription, and email a picture to anh.marketing@balchem.com. Include your size and mailing address, and we'll mail you a shirt.

In this episode of Your Dairy Checkoff Podcast, economist Dr. Oral Capps of Texas A&M University breaks down more than a decade of independent research measuring the impact of the dairy checkoff. Speaking from the 2025 Joint Annual Meeting, Dr. Capps shares how checkoff investments across food service partnerships, fluid milk innovation, whole-fat dairy science and exports are delivering strong, measurable returns for U.S. dairy farmers. He explains the rigorous, peer-reviewed process behind his analysis, the role of third-party credibility and why programs like lactose-free milk, whole milk, butter and product innovation have contributed to a turnaround in fluid milk consumption. Dr. Capps also offers a farmer-focused perspective on what the checkoff means for the all-milk price and what the industry could look like without these efforts. This is a revealing look at the data, the methodology and the real-world outcomes demonstrating that checkoff investments are paying off—and strengthening dairy's future. To learn more about the national dairy checkoff and your local dairy checkoffs, please visit dairycheckoff.com. Host & Guest Host: Scott Wallin, Vice President of Farmer Communications & Media Relations, Dairy Management Inc. Guest: Dr. Oral Capps, Executive & Regents Professor, Texas A & M University

The U.S. dairy industry is experiencing lower-than-usual commodity cheese prices, but Kim Heiman of Nasonville Dairy in Marshfield is betting on long-term growth driven by consumer demand for protein and significant industry investment. Higher-than-average temperatures mid-week may bring some precipitation, only to freeze later, says ag meteorologist Stu Muck. Grace Atherton with the Wisconsin Cheese Makers Association emphasizes that pasteurization effectively inactivates the bird flu virus, ensuring that commercially sold milk and cheese remain safe for consumption. Dairy processors are prioritizing food and employee safety with strict procedures. The Farmer Bridge Assistance Program has a deadline this week. Richard Fordyce, USDA Undersecretary for Farm Production and Conservation, says the first thing farmers need to do is submit an acreage report by Dec. 19. Market advisor John Heinberg discussed the minimal market reaction to Wisconsin's first dairy cattle bird flu case, while noting that grain markets are entering a seasonal window that typically offers price support and rally opportunities for corn and soybean farmers. He emphasized that current rallies should be used to protect against downward pressure ahead of the South American crop forecast.See omnystudio.com/listener for privacy information.

Talking popcorn business with Scott Trimble from Farmer Scott's Premium Popcorn in Heyworth. Kane County Farm Bureau highlights its "Eat, Join, Win" project. DTN ag meteorologist John Baranick says December weather will stay active, but turn warmer.   

Welcome to the True Fiction Project, your go-to podcast for exploring the journey of stories from their non-fiction roots to their fictional outcomes! I'm Reenita Hora, your host, and today we're doing something different and special. We have marketing strategy expert Saurabh Bajaj, Executive Vice President at Vodafone Idea and author of the fascinating book The Practical Marketer. We explore practical marketing strategies, brand positioning, consumer insights, and social media marketing. Saurabh reveals how category growth, market share, personal branding, and domain authority shape successful marketing campaigns and how those concepts can be applied to fiction writers and artists. He shares his digital marketing journey and the power of brand strategy. Tune in to hear his Cadbury Celebrations story—how a profound consumer insight about the Diwali holiday, "Iss Diwali Aap Kise Khush Karengay" (This Diwali, Who Will You Make Happy), inspired the iconic, successful campaign.What You'll Learn in This Episode: ✅ The fundamental brand strategy decision: pursue category growth or steal market share—this choice determines your entire marketing campaign approach.✅ Build personal branding and domain authority through social media marketing with vulnerable, authentic content that resonates with audiences.✅ How consumer insights and digital marketing evolved—why establishing context and authority matters more than keywords in modern practical marketing strategies.✅ The story behind Cadbury's iconic Diwali campaign and how understanding genuine human connection created a timeless brand positioning success.Subscribe to Reenita's Storytelling Den on Substack for free at https://substack.com/@reenitahora and to her YouTube channel to watch the video version of this episode! https://www.youtube.com/@reenymalCheck out her website to stay up-to-date on events, book releases and more! https://reenita.com/TIMESTAMPS:  00:00 Saurabh Bajaj, author of The Practical Marketer and how the pandemic sparked his writing journey 03:56 The fundamental brand strategy question: grow the category growth or steal market share08:03 Understanding your brand positioning task before executing any marketing campaigns13:33 Storytelling techniques for authors and how practical marketing strategies apply to creative professionals17:48 The evolution of social media marketing and building domain authority through authentic content26:11 Creating vulnerable, authentic content that builds personal branding and consumer insights32:00 Saurabh tells us an anecdote about the Cadbury Celebrations Diwali campaign story he spearheaded: discovering the power of genuine consumer connectionKEY TAKEAWAYS: 

In this episode of The Moos Room, Brad dives into a landmark new study examining the effects of short- and long-distance transport on the health, survival, and growth of pre-weaned dairy and dairy–beef crossbred calves. Drawing on data from nearly 392,000 calves across multiple farms and transport durations (ranging from 30 minutes to 24 hours), the study challenges common assumptions about calf transport. Surprisingly, mortality upon arrival was extremely low and unaffected by transport length. Differences in mortality by weaning (60 days) were also modest and, importantly, were driven far more by early-life factors than by time spent on the truck.The discussion highlights colostrum management as the single most critical factor influencing calf outcomes. Calves fed two colostrum meals had higher serum protein levels, significantly lower rates of failure of passive transfer, and were about 50% less likely to develop diarrhea—one of the leading causes of pre-weaning mortality. Other key drivers of calf survival included diarrhea, pneumonia, dam parity, gestation length, and birth season, with transport duration explaining relatively little of the variation in outcomes. Brad emphasizes that a calf's “destiny is largely sealed before the wheels start rolling,” underscoring that management decisions made at birth—especially colostrum feeding, dam health, and environmental stress mitigation—matter far more than transport distance alone.Questions, comments, scathing rebuttals? -> themoosroom@umn.edu or call 612-624-3610 and leave us a message!Linkedin -> The Moos RoomTwitter -> @UMNmoosroom and @UMNFarmSafetyFacebook -> @UMNDairyYouTube -> UMN Beef and Dairy and UMN Farm Safety and HealthInstagram -> @UMNWCROCDairyExtension WebsiteAgriAmerica Podcast Directory 

The Dairy Streamlet is a condensed version of a long Dairy Stream episode and covers the high-level points of the conversation. If this topic interest you, then listen to the full episode on Dec. 17. Kwik trip has been repeatedly named as a “Best Place to Work” both statewide and nationally and we dive into the specifics on employee culture. This previews a 2026 Dairy Strong conference presentation, register today at dairystrong.org. Dairy Stream host, Joanna Guza, and guest Ben Leibl of Kwik Trip discuss the Kwik Trip Praise Program, unsolicited guest compliments, employee training, motivators, how to start a positive culture, future goals for customer service innovation and employee engagement. Register now for the Dairy Strong conference Jan. 14-15 in Green Bay, Wisconsin About the guest Ben Leibl is a Public Relations Specialist for Kwik Trip Inc., based in La Crosse, WI. In his role at Kwik Trip, he assists coworkers with their ongoing educational needs and directs the Kwik Trip praise program, which last year meant acknowledging over 2600 unsolicited guest compliment letters. Prior to joining Kwik Trip in 2020, Ben was an instructor and principal in Oshkosh, WI and Omaha, NE. He holds degrees from Martin Luther College in New Ulm, MN. Ben sits on the Boards of the Boys and Girls Club in La Crosse, WI and serves as the Chair of St. Paul's Lutheran School Board. Ben and his wife Heidi have 3 children and they live in Holmen, WI. Compeer Financial is proud partner of Dairy Stream.  Learn more about Dairy Stream sponsorship. This podcast is produced by the Voice of Milk, a collaboration of individual dairy organizations working to improve the future of dairy farm families. Become a sponsor, share an idea or feedback by emailing podcast@dairyforward.com.  Join us at Dairy Strong on January 14-15 in Green Bay, Wisconsin. Gain timely political updates, dive into the dynamics of producer-processor relationships and learn strategies to sustain a stronger future for dairy through innovation and collaboration. United together, we're leading with purpose—one person, one policy and one farm at a time. To learn more, visit dairystrong.org.

Efforts to keep the heat on in Kentucky households this winter, Kentucky Youth Advocates releases its report on the wellbeing of children in Kentucky, small dairy farms turning to holiday agritourism to stay profitable, and Hall of Fame jockey Pat Day gets his own space at the Kentucky Derby Museum.

It's not just soybeans caught in the crosshairs of tariffs. The U.S. Meat Export Federation is battling against tariffs and phytosanitary challenges on the global scene, too. Dan Halstrom is the CEO of USMEF. He visits with Bob Bosold about the challenges and opportunities he sees. Halstrom notes that while some markets like China are still throwing up obstacles, there are still areas like Central America and regions of Africa that hold tremendous promise for U.S. meat products.Warmer weather is on its way, but it brings gusty winds. Stu Muck says the warmer weather will put a dent in the snowpack around the state by later this week. Wisconsin detected its first case of H5N1 and announced the findings on Sunday. Pam Jahnke gets the details on what consumers should know from Adam Brock, administrator of the Food Safety and Recreation Dept. at DATCP. Brock says with the rigid system Wisconsin put in place earlier this year, the impacted cow/herd was detected before milk left the farm. Brock also reiterates that even milk impacted by H5N1 is safe for human consumption once pasteurized. It's a different dairy story from the current Alice in Dairyland, Sarah Hagenow. She visits with Stephanie Hoff about how real Wisconsin butter adds a delicious element to the holiday season. Hagenow reminds consumers that if they want to know their dairy comes from Wisconsin, look for the "Proudly Wisconsin" badge or the number 55 on the dairy packaging. That tells you the product is Wisconsin-based. Paid for by Dairy Farmers of Wisconsin.See omnystudio.com/listener for privacy information.

Don Schaefer from Springfield, IL based Mid-West Truckers Association discusses a nationwide crackdown on CDL mills. Illinois FFA Center Assistant Director John Edgar highlights several conferences.Joe Camp with Commstock Investments previews a new market week.  

Australia beaks the record for most amount of beef exported in a calendar year, a surge in global dairy production and softer prices expected over the next six months, and the Kangaroo Island Ligurian Bee Company awarded for its agritourism business.

Welcome back to Everyday Homesteading. Today I'm sitting down with two people I deeply respect and always enjoy talking with, Shawn and Beth Dougherty. If you have ever wondered whether a family milk cow actually fits into a busy modern homestead, or if you've been feeling that tug toward a simpler, more land-rooted way of feeding your family, this conversation is for you.Shawn and Beth have spent more than twenty-five years raising a large family, stewarding rough Appalachian ground, and building a thriving homestead centered around the grass-fed family cow. Their new book, One Cow Revolution, takes everything they've learned and puts it into a guide that feels like having a wise neighbor over the fence.We talk about why the dairy cow is still one of the most powerful tools for food independence, how managed grazing can rebuild soil and family culture, and why the cow is far less of a burden than most people fear. Whether you already have a cow, hope to bring one home someday, or think you never will, you'll walk away from this episode with a whole new sense of what's possible.Let's dive in.- Grab a copy of One Cow Revolution here: https://a.co/d/gAx6o34- Check out the accompanying blog post here: https://homesteadingfamily.com/can-anyone-keep-a-dairy-cow- Thanks to Lehman's for sponsoring today's podcast. Be sure to check out all Lehman's has to offer at https://lehmans.com Time Stamps:0:00 - Introduction1:42 - Lehman's2:39 - Main Topic42:31 - One Cow Revolution (Book)~~~~~~~~~~~~~~~MORE ABOUT US!WELCOME! We're so glad you're here! We are Josh and Carolyn Thomas. Together with our eleven children, we are The Homesteading Family where we're living a self-sustainable life in beautiful North Idaho. Let us welcome you and show you a bit about us here: http://bit.ly/HFWelcomeVideoGrow, Preserve & Thrive with us!Visit us on our blog: https://www.homesteadingfamily.comFacebook at https://www.facebook.com/homesteadingfamilyInstagram: https://instagram.com/homesteadingfamilyRumble: https://rumble.com/HomesteadingFamilyA few highlights you don't want to miss are our FREEBIES!!Healthy Healing at Home – Learn how to confidently use herbal medicine in your home with this FREE 4 video workshop: https://homesteadingfamily.com/HHHytYour Best Loaf – A Free 4 video workshop teaching you how to make great bread at home, every time, regardless of the recipe you are using: https://homesteadingfamily.com/free-bread-workshopEvery single month we send out a physical magazine to over 10,000 people! It's filled with seasonal recipes, fresh inspiration for your kitchen, and practical homesteading tips from seasoned homesteaders. Just like the Everyday Homesteading podcast, the magazine equips and empowers you to thrive on your homestead. Sign up now for just $9/month. 

Holiday demand reminded the markets who's in charge — beef hit rare production levels while premium cuts held firm. As poultry and grains wait it out, pork stays a value and dairy keeps sliding into bargain territory. With the calendar about to flip, the real question is what holds… and what finally gives in the new year.BEEF: Holiday demand pushed production to a rare 600K head, but premium cuts are still commanding top dollar. The big question now – have middle meats finally hit their seasonal ceiling, and what happens next when the calendar flips?POULTRY: Chicken pricing stays calm and steady as we head toward the new year. But with avian flu cases climbing again, could this quiet market be one headline away from changing fast?GRAINS: Corn, soy, and wheat continue to tread water, moving just enough to stay interesting. Until something breaks the pattern, this market looks content to wait it out.PORK: Bellies bounced back this week, but the pork market feels stuck in neutral. With plenty of value still reminding buyers why pork stays on the menu, does this calm stretch continue into January?DAIRY: Cheese keeps sliding while butter barely blinks, turning dairy into one of the best bargains on the board. The question now – how much lower can it really go before demand steps in?Savalfoods.com | Find us on Social Media: Instagram, Facebook, YouTube, Twitter, LinkedIn

Highlighting Illinois Milk Producers Association award winners. Retired Will County Farm Bureau manager Mark Schneidewind reaction to his "World of Corn Award" from IL Corn.IHSA Friday Friday Friday segment features Lena-Winslow head football coach Ric Arand.   

Dr. Neal Barnard is a physician, clinical researcher, and founder of the Physicians Committee for Responsible Medicine (PCRM). He is a leading advocate for plant-based nutrition and has conducted groundbreaking studies on how diet affects diabetes, heart disease, and brain health. Dr. Barnard is the author of numerous bestselling books, including The Power Foods for the Brain and Your Body in Balance. Through his research and public education efforts, he has become one of the most influential voices in promoting evidence-based, compassionate nutrition.In our conversation we discuss:(00:00) – Misconceptions and origins of the plant-based diet(02:24) – Early exposure to heart disease and meat connection(05:11) – Discovery that plant-based diets reverse diabetes(06:07) – Portion control vs. natural body regulation(07:38) – Humans as plant-eaters, not natural carnivores(08:53) – Stone Age tools enabled unnatural meat consumption(10:22) – Returning to plant-based diets improves health(14:10) – Reversing diseases through diet changes and research(16:03) – What “plant-based” truly means and typical meals(17:33) – How fat buildup causes insulin resistance(18:53) – Three-week vegan diet and diabetes improvement(20:47) – Why omnivorous diets fail long-term(21:59) – Clarifying vegan vs. plant-based terminology(22:31) – Comparing keto and plant-based diet results(25:12) – Health risks and misconceptions of ketogenic diets(27:36) – The four pillars of a healthy diet(29:37) – Environmental and ethical impact of meat consumption(33:14) – Getting sufficient protein from plants(35:22) – Shrimp farming ethics and environmental damage(39:26) – Food production methods vs. health outcomes(41:31) – Protein intake debates and sarcopenia(45:03) – Plant protein sources and practical meal ideas(47:02) – Dining out and global vegan meal options(49:44) – Supplements: B12, D, iodine, omega-3s(54:06) – Iron sources and risks of excess iron(59:33) – Dairy, hormones, and links to cancer(1:07:06) – Compassion, evolution, and human indifference to animals(1:13:20) – Cultural and economic factors in diet choices(1:20:11) – Ethical debates about plants, pain, and life(1:23:22) – Dr. Barnard's books and closing reflectionsWatch full episodes on: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/@seankim⁠⁠⁠⁠⁠⁠⁠Connect on IG: ⁠⁠⁠⁠⁠⁠https://instagram.com/heyseankim

In this special live panel episode of the Uplevel Dairy Podcast, Peggy Coffeen moderates a discussion featuring three distinguished dairy industry leaders: Kylene Anderson, managing editor of Hoard's Dairyman, Brian Coyne Manager of Applied Genetic Strategies at Select Sires, and Amanda Lichtensteiger, Strategic Marketing Lead for Diamond V. This conversation was captured at the National Dairy Shrine Young Professionals luncheon during the 2025 World Dairy Expo. The panelists share their career journeys, from early internships to their current management roles. They offer advice on navigating the job market, building a career with intention, and the importance of mentorship and continuous learning. Whether you are starting your career or looking to advance, this episode is filled with practical tips and inspiration to help you stand out and succeed in the competitive dairy industry.

In this conversation, emergency medicine specialist Ankur Verma discusses the intersection of emergency medicine and metabolic health, particularly in the context of the Indian population. He challenges common myths about vegetarianism, highlights the importance of understanding cardiovascular health through data, and emphasises the role of nutrition in recovery. Verma also delves into the implications of vitamin D and B12 deficiencies, the dangers of visceral fat, and the need for informed dietary choices. Throughout the discussion, he shares personal experiences and insights from his practice, advocating for a more holistic approach to health and wellness.Chapters00:00 Introduction to Emergency Medicine and Its Challenges03:06 The Vegetarian Myth: Health Implications in India05:50 Understanding Heart Health: The Role of Diet09:01 Homocysteine and Cardiovascular Risk Factors11:50 The Lipid Hypothesis: Rethinking Heart Disease15:04 Patient Insights: Nutrition and Heart Health17:57 Vitamin D and Its Importance in Health21:00 The Impact of Visceral Fat on Health26:05 Understanding Visceral Fat and Its Implications30:10 The Role of Carbohydrates in Fat Accumulation33:39 Exploring Brain Detoxification Mechanisms35:13 The Impact of Dairy on Health39:12 Questioning Medical Guidelines and Practices43:27 The Importance of Nutritional Awareness47:21 The Role of Doctors in Patient EducationAnkur's LinksInstagram - @thecarnivore.epLinkedIn - Dr. Ankur VermaX - @ anksv25

There's milk everywhere: more milk in the U.S., Europe and New Zealand than a year ago, soft Class IV, and Class III futures that could slip into the $13s once you plug in today's spot cheese and whey. With a long milk wave crashing over the dairy industry, will farmers start culling cows and leaving stalls empty? Inside the episode, the team churns through: Why strong balance sheets, paid-down debt and high cow values could delay a production pullback How lower feed costs shift the breakeven – but can't fully offset falling milk checks Why Western and cheese-focused regions like the Pacific Northwest, California and Idaho may struggle first How WPC 80, WPI and clear whey proteins have become the lone bulls – and why capacity constraints limit the industry's response Why there are limits to what customers can pay for whey, and where substitution is already happening It's a barn full of bears on butter, cheese and fluid milk, but the protein complex is still flexing. The question is how long that can last? Tune in to The Milk Check episode 88: One bull in a barn full of bears to hear how our traders are navigating a market that's bearish on volume but still bullish on protein. Got questions? We'd love to hear them. Submit below, and we might answer it on the show. Ask The Milk Check Ted Jacoby III: Welcome, everybody, to The Milk Check. It is December 5th. We’re gonna talk about markets today. And rather than boring you and having the same conversation we had three weeks ago, everything is still bearish. There’s milk everywhere. There’s milk all over the U.S. There’s milk all over Europe. There’s milk all over New Zealand. There’s a whole bunch more milk this year than last year. Things are long. It’s very likely things are gonna get longer before they get shorter. Today we have some of our usual suspects. My brother Gus has joined us today. We’ve got Josh White, we’ve got Joe Maixner, we’ve got Diego Carvallo. And, of course, myself. Looking forward to a great conversation. So, rather than discussing how bearish we can be on these markets, my question, and I’m gonna start by throwing this question at my brother, Gus, is Gus, how long do you think it’s gonna take for dairy farmers to start culling cows and for this milk [00:01:00] production to slow down? Gus Jacoby: I feel like milk price and farm economics are completely contingent on that and how bad those farm economics get with respect to the milk price. Class III is still relatively high. Obviously, Class IV is pretty poor right now. The way I see it, dairymen, at this moment in time, still have fairly strong balance sheets. So, the recent low prices haven’t affected ’em all that much. So, I don’t expect their behavior with respect to culling and whatnot to change. But I think in five, six months from now, assuming that the milk price is at or lower, and quite frankly, I think Class III probably does need to get a bit lower, you’ll start to see some of that behavior change. If I had to guess, either as early as early summer, but as late as maybe mid-fall, if farm economics don’t change, we’ll start to see dairymen begin to leave stalls open. I mean, they’re gonna cull a cow, collect that beef revenue that they can grab, and not necessarily buy the expensive heifer. Ted Jacoby III: You’re thinking it’s gonna take about six months for dairy farmers [00:02:00] to get to the point where they feel like they need to increase the amount of cows they’re selling in order to meet their cashflow needs? Gus Jacoby: That’s my best guess. And again, that can be either expedited or slowed down depending on where the milk price goes. Ted Jacoby III: Corn prices have really come down this year. Do you think the lower feed prices have lowered where that break even point is, or how low we need to go in milk price in order to really send those signals in a strong way? Gus Jacoby: Certainly, feed prices being lower are gonna be helpful to the farm economic model. This becomes a milk price discussion. If the cheese price continues to have that downward pressure and gets low enough, those feed prices won’t be low enough. It’s always related to their inputs. And certainly, cheap feed helps their cause to extend growth in the milk production model. Ted Jacoby III: Right now, on December 5th, the Class III prices for the first quarter are right around, let’s call it $15.50, but if you use today’s cheese price on the spot market at the CME in today’s whey price, you’re probably looking at something closer to $14, 14 and a quarter. [00:03:00] Is that low enough or do we need to go lower? Gus Jacoby: It’s low enough. But not low to expedite anything. Maybe that takes us into the late summer, and remember, it depends on where we’re talking here in the country. Milk production costs are different depending on where you exist in the country. And also payouts are a lot different in a lot of places, depending on where you exist in the country. So, some regions might struggle sooner than later. Ted Jacoby III: Which regions do you think are gonna struggle first? Gus Jacoby: The West, Pacific Northwest, I think California, areas like Idaho that are strongly cheese based. If you’re paying on a Class III price and it stabilizes, which I don’t anticipate here, then perhaps some of those regions might hold on longer. My guess is predicated on the forecast of Class III going a bit lower. Ted Jacoby III: I guess I’d have to agree with that ’cause I don’t think $14 a hundredweight is enough. Because we’re still in front of Christmas, and I think the market’s probably gonna get worse before it gets better. My hunch is we’re gonna see $13 milk this year. We’re gonna see it in Class IV, and we may be already [00:04:00] seeing it in Class IV as soon as December. I think we’re gonna see a 13 handle in Class III, probably most of the first quarter. Gus Jacoby: If you’ve got a Class III at 13, and Class IV holds as low as it is, which I would expect certainly in the first half of the year, and then you have your standard freight and other deducts in those milk checks, dairymen are now getting to an area that is very adverse. Ted Jacoby III: Even though we’re talking about really low prices, I think there’s a lot of dairy farmers out there that are in a pretty healthy place. Gus Jacoby: I would agree. Ted Jacoby III: They’re healthy in two ways. One, I think that many of them have been able to take the last two years and really pay down their debt. And so, they’re in a really good spot financially, just on the balance sheet alone. But the second thing is those cows, they’re worth twice what they were worth three years ago. And so, not only have they paid down their debt, but if they need to borrow more, they’ve got more collateral to borrow against because those cows are usually the collateral for the banks when the banks lend dairy farmers money. It’s [00:05:00] usually the cows and the land. My hunch is that this may go on longer than we expect because of how healthy dairy farmers are financially today. Not saying they’ll be healthy in four or five months, but they’re healthy today. And because of how much bankers are probably willing to lend them based on those balance sheets. Gus Jacoby: I agree that the balance sheets are strong at the moment, even after a couple tough months. But I would also add, that that can change fairly quickly if the milk price gets low enough. And it’s certainly a ratio of farm economics over a certain period of time and milk price. If it gets low enough and makes those farm economics adverse enough, it can expedite the issue, which is a plausible scenario right now. Ted Jacoby III: Mm-hmm. I would agree with that. I think the hardest thing, especially when you have a falling market like we do right now, is to try and figure out exactly where the bottom is. About a month ago, the bottom was about a $1.40. Well, guess what? Cheese price is already below a $1.40 Now, we’re hearing it’s gonna be [00:06:00] somewhere in the $1.20s. What I’m scared is we’re gonna get to the $1.20s, and somebody’s gonna start talking about maybe we need to go into the teens. I don’t know if we’re gonna go that low, but we’re definitely in that scenario right now, where you have a market that’s falling and nobody has a really good feel for where that bottom is. Gus Jacoby: I agree. Cheese and butter right now, their outlook over the next six to eight months does not look good. Ted Jacoby III: Yeah. You mentioned butter. Joe, I’ll ask you: we’re below a $1.50 in butter. Butter feels like maybe it’s caught a temporary floor. Is this a temporary floor or could we stabilize here for the next six months? Joe Maixner: I think we’ve hit a temporary floor, but I don’t think it’s the lowest we’ll see over the next 90 days. I think that cream seems to be in balance, even after Thanksgiving, and I think it’s kept a nice spot in the market where people are willing to buy, those that hadn’t already put contracts on for next year are seeing the 2026 numbers and they’re looking at that against their budgets and blocking volume up for next year. A [00:07:00] lot of first half volume’s already been booked. We’re just seeing more activity. We’ve hit that level of support. Ted Jacoby III: Joe, you mentioned cream. Gus, I’m gonna go back to you. We had some really ugly cream multiples the first half of last year. Have we increased churn capacity, and do we expect those multiples to be just as bad this year or have we increased churn capacity enough so that maybe they won’t quite get so bad? Gus Jacoby: We have increased churn capacity, certainly. I don’t know if it’s enough. Some dairymen around the country are feeding their rations a bit different and getting a little bit less butterfat out of the milk. I don’t think that’s enough, yet, to make too much change. I will anticipate having some very low multiples through the holidays and the spring flush. Ted Jacoby III: Okay. Diego, I’m gonna switch gears and come to you. We just talked about U.S. milk production. Gus thinks it’ll take about six months to turn. I hate to be really pessimistic, but my gut, and I just can’t shake this gut, is it’s gonna take longer than usual this time around. And we may see it go well past nine months before we see a real turn. [00:08:00] We may see the number get better simply because we’re measuring against strength, but that doesn’t mean we actually see a change in trend. What about Europe and some of the other milking regions in the world, is it gonna take that long us to see some changes in milk production in those regions? Diego Carvallo: If you just go to the fundamentals and you analyze that the European farmer usually has a smaller scale, and that means that their costs tend to be a little bit on the higher end. They do not have access to capital as there is in the U.S. There’s more restrictions when it comes to environmental, and overall I would say they have more headwinds than the U.S. So, if you add to all of those headwinds, the price headwind, the reaction on milk production to lower prices should be faster than in the U.S. The same applies to South America. But we’ve talked a lot about Chinese production, we know that in that country, there are way more things to take into account. Ted Jacoby III: [00:09:00] So, we’ve been talking a lot about the supply side today. We’re just overwhelming supply on the butter side; we’re overwhelming demand to a lesser extent, but still on the cheese side. Josh, protein still tends to be the shining star. But are we getting to a point where we’re starting to get some pushback on protein prices? And is that going to continue to be the lone bull in an overall bearish dairy market, or do we need to be concerned there too? Josh White: I don’t think we’re getting pushback at the prices quite yet. Does that mean I think that these prices are palatable over the long term? I’m unsure. But what we are seeing right now is lack of availability and no quick ability by the European market or the U.S. market to scale production to meet the demand, which means that ultimately, the demand for WPC 80 and WPI and then some of the more value-added proteins, particularly in the whey complex, like the clear WPIs, the acidified products and others, the demand is outpacing our ability to supply it. What that’s [00:10:00] doing is forcing utilization segments or customers that can’t compete in terms of price for that available supply to look to alternatives. We’re starting to see more and more of that. As a commodity trader, we expect that to happen quicker than it does. So, already in early 2025, we were looking towards MPCs, casein-related products and others to pick up some of that demand because they’re much lower value. And I don’t think that the average customer in the market that’s using whey proteins fully recognize the functional differences between whey proteins and milk proteins. And they certainly don’t realize that milk protein concentrate has whey protein in it. Generally speaking, the average consumer doesn’t know the difference in these products. That’s not a fault of theirs. Particularly going into CPG applications and further processing, this is an ingredient. An ingredient that has a lot of label recognition and popularity right now for all the reasons we’ve talked about in prior podcasts: GLP-1 driven demand, [00:11:00] health and wellness movements globally, a lot of other reasons. Is that an early indication that enough time has now passed that the relative value of whey protein above the competing, but still quite valuable proteins in the dairy complex, are gonna result in substitution both substitution within the dairy category to whey protein to milk protein concentrates to micellar casein to WPC 70, also known as WPPC, whey protein phospholipid concentrate (WPPC) ProCream. There’s a lot of different names for these products. That’s likely to happen. But it also, unfortunately, might result in a lot of categories pushing to non-dairy proteins. There’s a lot of information out there, things put on by ADPI and others talking about the protein power of dairy and how digestible it is. How high quality it is for your conversion rate, why it’s such a popular thing. But if you can’t get supply, you’re forced to look to alternatives. And so, we’re starting to see some of that [00:12:00] happen. So, a couple things that I’ve heard anecdotally in the market over the past few weeks in particular, but it’s been happening over the last few months are: get us samples of milk protein concentrate. One of our customers is suspending a certain SKU on the shelf because they can’t get the supply. This price simply won’t work for our application. So, we won’t buy this product at above this price. So, we are triggering some thresholds. And triggering thresholds is gonna have some type of balancing result in the industry. Whether that’s enough to support the milk protein side of the equation, I don’t know. We have a limit to the ability to respond to this demand. You have to order equipment, you have to get the bank lending, you’ve gotta get the design. It takes a long time to increase capacity. That’s all gonna come into play and impact this market and the balance of this market in 2026. Now, if you’re asking me, is my gut that we hold these high prices or even higher prices without some reversal in the price [00:13:00] action for whey proteins in 2026? I’m not ready to say that it’s just here or higher in 26, but is it here or higher in the first quarter? Absolutely. Is it here higher in the second quarter, probably. Is it here or higher after that? I become a little bit skeptical. And to be clear, that’s not because the demand isn’t there right now. The demand feels like it’s there. I just don’t know how the market balances it out without pushing the price just too high in the short term for the market to digest it and pass it through. I also think that when you’re talking about the dairymen and you’re talking about the cheese makers, there is two different classes here. There is the class of those that make whey proteins and the class of those that do not. That has a material impact on profitability throughout the supply chain. Additionally, we’ve got a lot of milk in the U.S. We’ve got a lot of milk in the world right now, and the milk in the Northern hemisphere altogether is only gonna increase from here through the first half of [00:14:00] the year. That milk is gonna need to be processed. The incremental milk production will result in incremental whey protein availability, which means that those whey solids from cheese processors they have to find a market. If you can’t make the valuable product of WPC 80 and WPI, you have to explore the other alternatives, which are simply not experiencing the robust demand of those two categories. Sweet whey powder, whey protein concentrate 34% (WPC 34) and some of these other products, they have a limit to what people are willing to pay. History tells us, at least for sweet whey powder, we’re testing those limits. Ted Jacoby III: For sweet whey powder, we are, the question is, is this happening for whey protein? And that’s a harder one to answer. Josh White: Absolutely. Ted Jacoby III: I did some back of the envelope math. As a country, we produce 8% to 9% more milk in May on a daily basis than we do in November. If half of that milk goes into cheese, we’ll produce 8% more cheese and 8% perhaps more whey protein. The solids change, too. So, maybe it’s not a full [00:15:00] 8%, but is 8% enough to tip the scale on whey protein demand? And I don’t know, given the demand complex for whey, I think for cheese it’s gonna feel very burdensome. I think for butter, it would probably feel pretty burdensome. The butter market we’re kind of used to it because of the way the demand curve looks, but I just don’t know when it comes to whey, if that’s enough to put some pressure on this market and bring those prices down. Josh White: Well, it depends on what you’re talking about because you could argue that the WPC and WPI facilities are bringing in outside whey solids. Mm-hmm. Mm-hmm. As their own milk and their own whey generation increases seasonally, that’s gonna push whey solids back to somebody else. So, all 8% in your hypothesis there, I doubt contributes to an 8% increase in whey protein production. Because the available capacity isn’t there? Josh White: Correct. Now, is there production efficiencies that are still gonna be gained? Are there those out there that are expanding a bit [00:16:00] that we’re unaware of? Are there orders for new equipment in the system that might be closer to realization than we think? All possible. And we can’t ignore Europe. I don’t feel like I can adequately represent what the expansion model looks like in Europe right now for whey proteins. What I can say is that at least for the U.S. and Europe, our internal demand is currently absorbing a greater percentage of our production than ever before, and that’s leaving the rest of the world that was buying product from those two markets, having to search for that protein elsewhere. Ted Jacoby III: Mm-hmm. Josh White: And, this is being a bit over generic, but the rest of the world likely will be more willing to substitute than the U.S. or the European consumer to other products. Ted Jacoby III: I would agree with that. Everybody in our office is just leaning really bearish, just about everybody we talk to seems to be leaning really bearish. Josh White: Outside of Black Swan events: major trade disruptions, major production impacts that we can’t predict. If you’ve [00:17:00] been in the dairy industry long enough, you know to never bet against the dairymen and their ability to make milk. But it’s gotta be on the radar that the competitive dollars for those animals I don’t think has ever been as lucrative as it is right now. And those animals that they’re currently milking are older then typically they want them to be. So, if we shift this cycle quickly enough and violently enough, and that’s price, at what moment do we get surprised at what that residual response is? How many pent up animals find their way to slaughter? How quickly that could happen. And I think generally speaking, most of us would bet that the calf inside the dairy cow right now is worth enough to wait. And so, we’ve gotta get through the first half of the Northern Hemisphere season before we see much of an animal response. Ted Jacoby III: I think that’s a fair comment. Dairy farmers, especially the big financially astute ones, there’s a math equation. It’s like, this is my revenue [00:18:00] from milk. This is my maybe revenue from biofuels or wherever else. They have revenue streams from a cow that’s giving milk every day. This is the cost to maintain that cow. The variable cost feed, for example, being the big one. Well, when you’re getting $20, a hundredweight from your milk versus $13, a hundredweight for your milk. That equation has changed quite a bit, whereas the exit price, what you’re gonna get if you sell the cow hasn’t changed at all, which means your math equation, the exit possibility has definitely gone up. It’s more profitable to sell this cow than it used to be. Josh White: History tells us that the exits of the older dairymen and the smaller dairies doesn’t really change based on economic conditions, it’s relatively stable. Maybe there’s some risk that we have some pent up exits and some risk that it’s never been a better time to retire. Mm-hmm. And you get some smaller dairies that decide to exit. That doesn’t move the needle. Ted Jacoby III: I would suspect. You’re right. We’ll see. Josh White: One [00:19:00] quick remark that’s important is the outlook on demand. It seems like the market is very, very bearish because supply is outpacing demand globally and it’s in every major milk shed. But demand by import regions has been pretty good. Mm-hmm. They’ve been buying year over year, more dairy products. At the same time, I don’t believe there’s any region in the world that’s currently sitting on cumbersome overall dairy stocks, whether that’s from the import regions or the production regions. Everyone seems to be quite aware that you gotta stay in front of this. I don’t know how to interpret that. On one hand, you could say that based on some of the economic outlooks, globally, we shouldn’t be expecting things to get better. We should be expecting them to get at best the same or possibly even worse. On the other side of that equation is import dairy consumption and demand is growing and continues to grow, so it might be a painful period, but the long-term [00:20:00] outlook remains pretty good, and we just overreacted to some of the demand signals that we have. Credit to the dairymen in the world, being able to respond to signals that we needed more fat, not even a year ago. That whey protein demand’s good. I mean, the market has responded, but overall we’re not talking about an oversupply situation because demand’s bad. If you go granularly, like U.S. cheese consumption, doesn’t look real great right now. The outlook for overall economic health, I’m not an expert in that area, but I’m not seeing a lot of people talking about a rosy 12 to 24 months there. So, yeah, I think generally speaking, it’s easy to be bearish, but maybe that’s one thing to pay attention. Ted Jacoby III: You mentioned demand. I happened to be involved in a conversation yesterday with an equities trader and his comment about stock valuations, equities, valuations, which was really a demand comment, was, I’m just waiting to see what Christmas sales do. I think there’s a lot of people out there right now that are trying to get a feel for what’s [00:21:00] the long-term demand or the 2026 demand perspective, and I think a lot of them are gonna judge what it really is based on how this holiday season plays out. All right guys. Hey, thanks for a great conversation. I apologize to all the dairy farmers out there that I couldn’t give you any better news, but hang in there that good news will come eventually. That’s right.

2025 was a pretty good year for most county fairs in Wisconsin. Jayme Buttke, executive secretary of the WI Association of Fairs, joins Pam Jahnke for a brief wrap-up. One major project that the state undertook this year was an economic impact study. What does a county fair mean financially to the county and the state? Buttke says they'll be sharing that information with members during their annual meeting in WI Dells come January. The snow has largely moved through the state, and now here comes the cold. Stu Muck says if you need to do outdoor chores or patch up any holes - do it today. The weekend will be sub zero. Just like solar arrays, wind turbines and data centers, the cry of "not in my backyard" can be heard when it comes to farms expanding. Stephanie Hoff talks with a farmer caught in some of those conversations. Brad Olson is not only the president of the WI Farm Bureau Federation, he's also a farmer in Polk County where groups are crafting unique ordinances to put heavy constraints on how agriculture grows - IF it can grow at all. Olson says most of these town and county boards are not prepared for the "loud voices" that want to essentially stifle any agriculture growth in their geography. More milk, more milk, more milk. It's the mantra draining the energy from the dairy complex. Zach Bowers with EverAg joins Pam Jahnke to discuss how the industry's approaching the new calendar year with incredible supplies to work through. He says there are some dairy processors that are pivoting to capitalize on the growing protein demand in the U.S.See omnystudio.com/listener for privacy information.

Leslie is joined by Scott Kroona and Brad Lusk, members of Teamsters Local 120, which represents over 15,000 workers in Wisconsin, Minnesota, Iowa, North Dakota, and South Dakota. They discuss why their Union has authorized a strike at Actus Nutrition and Foremost Farms. They explain what has led to the strike, and how they and other dairy workers are pushing back against cuts to their health care, pensions, and other protections. The website for Teamsters Local 120 is www.TeamstersLocal120.org.

Eating Meat After Dairy (3) by Rabbi Avi Harari

Jennifer Keeley and Mary Whittenhall, experienced nurse practitioners in the field of pulmonary hypertension, discuss the management of cough in patients receiving inhaled therapies for pulmonary hypertension and interstitial lung disease. #GossamerBioPartner #sponsored This Special Edition episode is sponsored by Gossamer Bio. Jennifer Keeley, DPN: My name's Jennifer Keeley. I'm a nurse practitioner and I practice in a large academic institution in Pittsburgh, Pennsylvania, Allegheny Health Network, specifically Allegheny General Hospital. I am a nurse practitioner there and have been in the clinic over 10 years, and in the PH space as a nurse practitioner for over 15 years, as a registered nurse for almost 20 years. So, I have a lot of experience and I'm really excited to be here today to talk about inhaled therapies and cough. Mary Whittenhall, MSN: My name is Mary Whittenhall. I'm also a nurse practitioner. I am currently an advanced practice provider at Pulmonary and Sleep Associates in East Providence, Rhode Island. I've been in pulmonary hypertension for about 11 years now. In that time, I have worked in a variety of settings, both inpatient and outpatient, managing patients with pulmonary vascular disease, and have also touched upon patients with interstitial lung disease and pulmonary hypertension.  I get very excited when I hear about new opportunities for our PH patients. I think a lot about even when I started in pulmonary hypertension and the therapies that were available to our patients. Many of these therapies had been around for a little bit of time. But also something that I think is extremely exciting is that there's just been a rapid progression in development of therapies. And now, with the focus of looking at these therapies as potentially disease modifying, not necessarily slowing the progression of disease. With the advent of all of these new therapies, there become more options for our patients, as well. Often, patients can't tolerate some of the medications that we have due to side effects and despite lots of work to manage these side effects, the patients are not always successful. One of the great things being involved in an academic center is that we have the ability to help link patients to cutting edge research, particularly looking at a new drug that is an inhaled therapy that has shown significant promise in improving the lives of patients with pulmonary hypertension. As a part of the PH community, we all do quite a bit of networking with each other, as well as with our patients and other colleagues in the space. In that time, we did network regarding the study and have participated in some activities where we're looking at the data from the Phase 2 part of this trial and then also looking at some of the side effect management related to the medication, which seemingly is well tolerated. However, for some patients it may not come extremely easy. I think that's where the role of the nurse or the advanced practice provider really comes in this space is that we have a real strong dedication to helping educate patients about ways to manage these side effects. We want patients to be able to continue with therapies. We don't want them to say, "Well, this isn't working for me, it's time to move on." I think that we have a lot of strategies and a lot of experience with trying to help patients really figure out the best way to manage these things and to be confident that they can continue on with obviously the biggest benefit of improving their pulmonary vascular disease. Jennifer Keeley, DPN: We actually met at an advisory board last year. It was an advisory board consistent of registered nurses and nurse practitioners who, just like Mary and myself, have vast experience with patients and therapies, not just in the inhaled space, but more conventional pulmonary vasodilator medications that have been used in our patients for many, many years. As Mary had suggested before, when we start to think about newer agents, many, many of them are not the conventional pulmonary vasodilator medications, but disease modifying agents. Now, we've acquired an armamentarium of medications. So, inhaled delivery is just a really great option to avoid systemic side effects on top of each other. Our PH patients today, many of them are on more than three therapies, many of them are on four or even more therapies, so the delivery of the medication is just one aspect. When we talk about cough and side effects, I like to think about it and explain to my patient when we talk about side effects, particularly cough, to imagine a Venn diagram with cough being in the middle and what affects cough. You see this outward circle, how we deliver it, what kind of device we deliver it in. The drug, how small, large are the particle size? Is it easy enough to use for our patients? The formulation, is it dry powdered versus inhaled aerosolized? And then finally, just the patient themselves. What's their background? What type of PAH do they have? So, we can talk a little bit more about this, but just to get us started, this is how this developed and we had a lovely advisory board meeting with seralutinib and Gossamer Bio, and this was the outcome of it. We produced a lovely poster. This is a conversation if you will, that Mary and I are going to have based on what we talked about and the poster production, that came out of that wonderful advisory board. Mary Whittenhall, MSN: Inhaled therapies are unique in a way in that they actually have direct access to the lungs. So, when you think of an oral medication, an oral medication needs to be digested in the gut and sometimes that systemic digestion takes a while. Additionally, it's also often that we see patients that have more systemic side effects when we're using an oral formulation. Intravenous or subcutaneous formulations of these medications tend to cause pretty strong systemic side effects for patients, and there tends to be a lot of management that we need to do to help make these side effects more tolerable. For most of our patients, I say to them, "You're going to think I'm cruel because I don't really want these side effects to go away." In a way, we look at them almost as if you have a cup and your cup is full of water and after the top of the water hits the rim of the cup, then the water starts to spill over onto the sides of the cup. I think of other medications that we typically prescribe for patients in that way that when we get that spill over, so to speak, it's an indication that we've actually targeted all of those receptors that we want to help with vasodilation. Now that we're looking at other medications that don't really necessarily look at vasodilation, we're looking more at treating the blood vessels in a different way or affecting the process for which those blood vessels become diseased. I think that the side effects become different and I think they become less. In working with inhaled therapies, as you can imagine, the number one side effect that most patients will complain of is cough. Sometimes we have patients who have an underlying cough already, and that's usually not related to PAH, but in PH-ILD where we now have an FDA indication to use another inhaled therapy, we've seen in treating these patients that baseline cough is something that is extremely problematic for them before they even start therapies. So, trying to find ways to improve that baseline cough, treat any underlying symptoms, things like acid reflux as well, that may cause that, treating seasonal allergies, et cetera, and then, obviously, managing any additional overlapping side effects that may occur because of the new therapy that they're on. Jennifer Keeley, DPN: I think that's a really important part, is to talk with the patient, educate the patient on these inhaled therapies. First and foremost, that cough is almost an expected side effect. These are patients particularly with our interstitial lung disease patients that have PAH, cough is a part of their daily life. It's important to document and ascertain what these patients' baseline cough is. In many, many clinics, particularly pulmonary PAH clinics, and I'm sure much like Mary's, many of my colleagues have recommended using validated cough questionnaires so that we can get a really, really good baseline of what that patient's baseline cough is. Are you coughing at night? Do you have mucus? How long have you been coughing? Does it interfere with the quality of your life? Do you cough at night? Does it keep you up? Does it interrupt your sleep? Those kinds of things that help differentiate acute cough versus chronic cough. Many of these patients cough every day. They also have other inhaled therapies such as our ILD patients that are also on corticosteroids, many of them on inhaled corticosteroid therapy that can thin the oral pharynx, the posterior pharynx, and really affect the degree of nerve innervation in the posterior pharynx in the mouth. So, just really understanding what the patient's baseline cough is and educating them on the fact that cough is likely going to be a side effect with the use of this inhaled therapy. Certainly, as we continue to use the therapy, we would hope that the cough can be mitigated either through some lifestyle modifications, some natural remedies, and even some medical remedies such as bronchodilators. But really teaching the patient about the medication and inherently that this is likely going to induce a cough, but that we have mitigation strategies to help dissipate the cough. I always like to tell my patients also in the clinical trials, particularly the Phase 2 clinical trials that are out there that patients had a lot of cough. The patients on drug that were in most of the Phase 2 clinical trials for seralutinib and even for treprostinil inhaled, 30 to 40% of them experienced cough. But at the same token, the placebo-based patients that did not receive drug in these Phase 2 clinical trials also had a lot of cough. So, what that's telling you is yes, you're going to get probably some more cough, but it's likely not going to be that much or more far advanced than the cough that you're already experiencing. I also think it's important to tell these patients, many, many patients that experienced cough did not stop the medication. Actually, in these Phase 2 clinical trials, very few stop the medication. So, that gives you a really good big picture that we are pretty good at educating our patients how to mitigate cough, and if we aren't, then we should learn how to do so. Mary Whittenhall, MSN: I think it's important for us to set some expectations for patients when we're talking about cough. We've already discussed a bit that cough can happen for people from other things outside of their lung disease, but it's important to also look at what may be causing the cough when we are giving a patient an inhaled therapy. So, any type of inhaled therapy, whether that be a dry powder, a mist, whether that's nebulized or through in actuated inhaler, there are particles inside of that medication as it's going in and those little particles, when your lungs inhale that medication, those particles are penetrating your lungs and your lungs are not accustomed to them being there. It's almost as if your lungs are saying, "I don't recognize this. I don't know why this is here," and it may feel like it's an irritant, so you may start coughing as a result of that, but the cough is not necessarily a bad thing. Those particles are there, and the job is to essentially help deliver the medicine to penetrate that lung tissue and then for your body then to absorb the medicine. Your airways and your blood vessels inside of your lungs are extremely close to each other. So, when you inhale that medication, those little blood vessels are also right next to where those airways are, and then that is how those blood vessels then absorb that medication, because they're so close to the site at which those particles come into your lungs. Jennifer Keeley, DPN: I think this is an important concept to understand. They choose the form of delivery based on the goal of delivering the most medication efficiently to the distal bronchioles. That's where the disease is. It's in the distal arteries. So, trying to formulate how we get these very powerful, oftentimes disease modifying agents into the periphery of the lungs can be very challenging. Dry powdered inhaler is one form that the variability of delivery is not as dispersed as an aerosolized. So, it's more efficient delivery to the place where the medication needs to work the best, and that's in the distal periphery of the lungs. Unfortunately, one thing you have to deal with is that oftentimes these medications, dry powdered medications, not just in the PH space, but there's a lot of other dry powdered inhalers in the COPD space, as well. Oftentimes, what happens is these powdered particles get dispersed extra thoracically. So, they get dispersed in the oral mucosa, in the posterior pharynx, on the way down into the stomach. That's wherein we have to deal with mitigating side effects. The biggest side effect of these particles, even though they're very small, is cough. So, technique comes into play. Mitigating things to coat the posterior pharynx come into play. Re-education comes into play. Show me again how you're doing this inhalation, because I don't think that you're holding this okay. In one instance, I had a patient that was inhaling dry powdered inhaler with the medication right out of the refrigerator. So, the medication was cold. It was clumping at the back of her throat. All of these things really take into consideration how we most efficiently get the medicine to these pulmonary arterial hypertension patients where their disease is oftentimes very difficult to get to, and other forms of medications that are systemic, orals, parenterals that have first pass metabolism, and so you're going to get more side effects from those medications. So, I always teach my patients, "Hey, we're a couple steps ahead because we're bypassing the type of metabolism that you get with orals and even parenterals." Mary Whittenhall, MSN: There are so many challenges that these patients face. Oftentimes, patients have never been sick before they develop this, and now we're putting them on multiple therapies, multiple modalities, telling them that there's going to be side effects and they need to learn how to manage them. It's certainly a lot to handle. But I think one of the best things that we have in our PH community is that we really work so hard to partner with the patients and their loved ones and forming this relationship, fostering that relationship as time goes on, I believe that these patients really do trust us and that what we're telling them is things are going to be okay. We are going to be there by your side. We're not going to give you this medicine and then say, "See you in six months. Hope everything goes well." We're really going to be working with them. In some cases in my specialty clinic, we have nurses, we have a pharmacist, a pharmacy tech, and then our advanced practice providers that check in with these patients quite regularly. We are actually taking the initiative to reach out to them versus the patient who may be having trouble advocating for themselves or feeling like, "Really, I don't want to be a pain, but this is challenging for me." We are really in touch with them, and that connection also helps to keep patients on therapy. So, what are some of the specific techniques to manage or mitigate cough? This is something that was a real hot topic at our last advisory meeting. We put together a bunch of folks in the room who deal with other inhaled therapies and patients that have cough and said, "Well, what do you tell patients to do?" First and foremost is to look at any other potentially underlying conditions that may be causing cough and ensure that treatment of those underlying conditions is optimized. I think cough is actually the number one referral for any type of pulmonary practice, but it is a really, really broad differential when it comes down to it. We obviously look first at things like environmental factors. If this could be seasonal allergies, then we try treating patients with antihistamines. Perhaps some of those are intranasal, as well, that may help with some things like rhinorrhea or post nasal drip. Acid reflux is actually a huge, huge reason for cough. Many patients say, 'Well, I don't get acid reflux. I don't feel that burning in my chest after I eat," but come to find out that it can actually be a silent trigger. So, treating patients with medicines that help to reduce acid or suppress acid will oftentimes help with that cough. On top of that, when we're dealing with patients that are on inhalers and now we're adding another inhaled therapy. I find that for some patients that are on actual inhalers that sometimes they do better with nebulized treatments. The nebulized treatments are slower, and may have a bit of a better penetration into the lungs and the patients tend to like it. It is one of those things that you do need to be compliant with in order to really see the benefits to it. I will say that oftentimes, again, partnering with the patient, giving them specific instructions about how to do all of this, we can really see some improvement to those symptoms. Then, there's just basic over-the counter measures and precautions, things like making sure that when you're eating that you're not laying down at least for 60 minutes after you've been eating. If you do have acid reflux, trying to sleep with two pillows or a wedge pillow, that can help to keep the head of your bed elevated. Some of our patients have those really fancy adjustable beds that are also quite helpful for that. I think that sometimes things like basic cough drops actually can be quite wonderful and helpful. Drinking very cold or very warm water or tea, adding some honey to that if a patient isn't diabetic, things like that tend to really help with cough. We reinforce these measures when we start therapies like this. Jennifer Keeley, DPN: In terms of mitigation, I think it's really important on technique. This is why, as Mary had alluded to, it's so important to follow up closely with these patients, particularly our elderly patients who sometimes don't, if they have connective tissue disease or scleroderma, have a lot of good fine motor coordination. A couple of things that I wanted to touch on with regards to that… One, these inhalers are typically high resistance, low flow. So, these are not the type of patients that need to be taking in very forceful inhalations with these inhalers and thank goodness, because we're talking about patients that have inflammatory interstitial lung disease, as well as pulmonary vascular disease. So their degree of inspiratory effort is actually minimal to disperse that medication to the distal pulmonary bronchials. It's equivalent to them taking a deep breath in when you ask them to auscultate their lungs. So it's not a big forceful breath. The other thing is too, a lot of times, sometimes more variability in the disbursement of the drug is better in compliance with some patients. Dry-powdered inhalers, again, do not take a very big forceful effort, but some of them, because they are powder, some of the medication will actually hit the back of the throat as it goes down and can cause some irritation, whereas the nebulized form does have a variability in disbursement and can be more easily tolerated in some. The other issue is the technique itself. Oftentimes, we ask them in some of the inhaled therapies to lower the device itself so that the tongue doesn't protrude and get in the way, because if medication gets on the tongue, the next swallow that they take, that medication is going to hit their posterior pharynx, and they're going to probably cough pretty aggressively. I always start off by telling my patients, "Cough is not a bad thing. It's actually a protective reflex and it's involuntary. So, if you cough, don't actually negate it. Don't think it's a bad thing." It's actually a very protective mechanism that avoids irritation in most of our patients probably already irritated mucosa. So, that's how I like to start the conversation. There's so many good techniques that we can share with them over time, and I might add that each patient is different. Each patient needs to have a personalized plan. When we talk about giving patients warm tea, typically chamomile, chamomile tea in itself is anti-inflammatory. Then, when you add something like honey, which is also a soothing, anti-inflammatory natural remedy, you have to really think to yourself, "They're getting honey. If they're diabetic, we don't want to give them too much honey." But, you have to make sure that their swallowing technique is good. There's no aspiration there, particularly if we give them cough drops. Then, just simple things that actually numb or anesthetize the back of the throat are very, very helpful for elderly patients who do have very friable tissue and mucosa from previous therapies like inhaled corticosteroids, as I had talked about before. Dairy products, I tend to ask my patients to avoid those. They can produce a lot of mucus, which these coughs that we see in our inhaled therapy patients are typically tend to be dry coughs, but some patients that have concomitant asthma, COPD, along with their ILD that are using these inhaled therapies can actually have more of a congested mucoid cough. So, avoiding dairy before and after use is always very smart. Avoiding alcohol, avoiding acidic drinks like orange juice, also very, very helpful. Mary Whittenhall, MSN: The part about technique I think is so, so important here. Oftentimes, when patients start these therapies, when they are approved in that space, the specialty pharmacy has a nurse educator that will come out to the patient's home and provide education not only about the medication, but about the administration of that medication. In many cases, the patients will take their first dose while the nurse is present so that the nurse can then critique whether or not the patient took it appropriately and how they tolerated it. I'm going to give a shout out to our nurse educators from the specialty pharmacies, because they are also a really crucial set of eyes and ears for us out in the community. They do provide education to the patients in the home. We have had situations where the patient has done well while the nurse is there, and then two weeks later we get a call from the patient saying, "I can't do this. This isn't working for me." And I'll say, "Okay. Well, you have a couple options. We can have you come in to the clinic and I want you to bring your device with you, and I would like to watch you do a treatment, or I can have the nurse come out and see you again and go over that." And they'll say, "I already know what I'm doing. I don't need that." But in many instances, we have found that they have adjusted their technique. They might've gotten into some bad habit since the nurse has left them. So, really reinforcing that is important. The other thing that I wanted to bring up is that some of our patients with connective tissue disease also have thickness in their tongues. So, their tongues become thicker and more sclerotome as their connective tissue disease progresses. For some of those patients, it is actually hard for them to get their tongue flat enough so that they can get the medication down into their lungs. So, working with those patients to find strategies to help rectify that. I will say that it is not impossible, it just takes maybe a little extra work. Jennifer Keeley, DPN: Inhaled therapies in themselves are pretty portable. Mary had alluded to a little bit earlier, our patients with pulmonary vascular disease, PAH, that are on parenteral therapies, delivering the conventional pulmonary vasodilator therapies. As we get into the new disease modifying agents such as seralutinib, which are anti-fibrotic, anti-inflammatory, anti-prolific medications, these are portable therapies that are actually modifying the disease. So they're portable. They're easy to use. They're easy to use for our patients, again, that are elderly or are younger and are still working, they have a professional life, they don't have to wear a pump that's 24/7 oftentimes. They can use these inhaled therapies first to see if they can avoid parenteral therapy with prostacyclins. Their quality of life is improved immensely. When you can take an inhaled therapy two to four times a day and really improve quality of life, decrease cough, decrease dyspnea, or shortness of breath on exertion. Sometimes, these patients that do very, very well can actually reduce their supplemental oxygen needs. Just improving their walk distances without having to stop or have excessive dyspnea, improves their quality of life. More time spent with loved ones and more time spent in social environments rather than sitting at home. These wonderful inhaled portable therapies have significantly changed our patients' lives and improved their quality of lives. Mary Whittenhall, MSN: This community I think is phenomenal. It's made up of so many great people. There are many patients who have been a part of this space for a long time who really want to help other patients who may be newer to the journey than them. I'm a big advocate for support groups. We've had an extremely active support group in our area for a long time, and I often partner some of my patients that have been with me for quite some time with some of the new patients that may need a bit more help. I can tell them things and my colleagues can tell them things. Oftentimes, the same message doesn't resonate. It resonates differently, I think when it comes from a peer, a patient who may have experienced the same thing as them. One of the things that I really try to drive home with our patients is just that sense of empowerment. Connect with these other folks in the community. They want to help you. They remember what it feels like being newly diagnosed or starting a new therapy or transitioning from another therapy. What that change is like. One of the other things I tell my patients is that we all sit at the same table. I'm not better than you. Maybe I have this information, but this information is for you. It's for you to take and to improve your life. If that information doesn't work for you, then you come back to me with some feedback and we come up with something else that's going to be more helpful to you. I really think having an equal playing field with them and having a very open and honest dialogue is what is going to help our patients do the best. If patients don't feel comfortable reaching out to other local patients or connecting with an in-person support group, there are tons of online resources through the PHA, through phaware®, Team Phenomenal Hope, lots of great groups out there that do things virtually. I think in some ways for some patients, anonymity is important, so being able to protect that is an option for them, but to be able to still get what they need so they can become the best advocate for themselves that they can. Jennifer Keeley, DPN: I stress so importantly to my patients, we are here today in this great environment and we have the armamentarium of medications to treat because of patients just like you that have contributed to the science of the disease and implemented themselves and engaged in these clinical trials. Right now we have an ongoing clinical trial for seralutinib called PROSERA, that's enrolling as we speak. Patients are the best advocates, not only for themselves, but for other patients, and they talk. There's a lot of social media out there where patients communicate amongst themselves and they say, "Through the help of my provider and through the help of my family, I was hesitant to start this additional therapy." They do have, at this juncture, and I don't think it's such a bad thing, they do have a little bit of a pharmacy burden now. Again, these aren't our patients that are on one or two therapies. They're on four or more oftentimes. When you take in our ILD patients, they're also on disease modifying agents, as well, for their interstitial lung disease. So again, I think it's really important for patients to communicate amongst themselves and share their ups and downs in the disease, but also share the rewards that come with surviving and living with PAH. I think one thing that we really do have to understand though is like many other chronic diseases, PH is a personalized disease. You need to have a personalized approach for your patients. That's why it's so very important to do a really good history of your patients and understand not only what their baseline cough is, but who they are, what their personal history is. Are they working? Who's helping to care for them? Who's helping to make that chamomile tea with honey? Who's going to the store to get that? A personalized approach is so important for these patients, I can't stress that enough. Mary Whittenhall, MSN: Special thanks to everybody involved in this project. This was extremely exciting. To my co-podcaster, Jennifer Keeley, who is amazing, and all of us in the PH community are extremely lucky to have her. We are all aware that you are all rare, and we are grateful to be able to help you in this journey. Jennifer Keeley, DPN: Thank you so much, Mary, and what a pleasure it's been to speak with you about cough and inhaled therapies, and thank you to Gossamer Bio for this opportunity and for the opportunity that led to this podcast, which was a significant advisory board amongst specialists in our field, advanced practice providers and registered nurses who were able to convene in a great open space and talk about this. I think this moves our science forward. It helps us to talk about the disease and take better care of our patients. Again, my name is Jennifer Keeley. It's been such a pleasure to deal with my good friend Mary Whittenhall today, and we're aware that our patients are very rare. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Follow us on instagram, facebook and x.com @phaware. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. #phawareMD #PHILD @GossamerBio @AHNtoday

Leslie is joined by Scott Kroona and Brad Lusk, members of Teamsters Local 120, which represents over 15,000 workers in Wisconsin, Minnesota, Iowa, North Dakota, and South Dakota. They discuss why their Union has authorized a strike at Actus Nutrition and Foremost Farms. They explain what has led to the strike, and how they and other dairy workers are pushing back against cuts to their health care, pensions, and other protections. The website for Teamsters Local 120 is www.TeamstersLocal120.org.

Dr. Lock presented a Real Science Lecture Series webinar on June 3, 2025. This episode takes a deep dive into the current science and applications of feeding high-oleic soybeans in dairy diets. You can find the original webinar at balchem.com/realscience. Dr. Lock gives an overview of the evolution of our knowledge of biologically important fatty acids in dairy cows. Much like we think more about amino acids than crude protein these days, we are starting to think about fatty acids rather than crude fat. There are 5 main fatty acids in dairy cow diets: palmitic, stearic, oleic, linoleic, and linolenic. Dr. Lock talks about the importance and role of each, especially that of oleic acid. (6:26)  Dr. Bales shares some of the research she conducted in Dr. Lock's lab during her MS and PhD, including a dose response study, raw versus roasted beans, and roasted beans plus supplemental palmitic acid. All studies have resulted in increased milk fat and milk yield, better feed efficiency, and usually a bump in milk protein. She also notes there is a nice synergistic relationship between the fat and degradable protein in the roasted high-oleic beans, which are high in lysine. (13:59)Nate talks a bit about how the elevator positions high-oleic soybeans to the dairy producers in the area and how different farms have implemented feeding the beans, depending on size, infrastructure, and location. Dr. Bales chimes in with some additional examples. (21:02)The panelists agree that quality control to ensure consistent sources going out into the field is the next big hurdle. Finding the optimal particle size for diets is also needed, as there is a wide variation currently, which may impact cow performance. (31:56)Nate predicts no slowing down in the adoption of this technology in his area in the next few years. Dr. Lock notes there may be some potential for feeding high-oleic oil in areas not suited for growing the beans themselves. The panelists agree that the target groups who should receive high-oleic beans in their rations are fresh cows and high cows. Nate emphasizes the importance of having adequate digestible NDF and a healthy rumen to see optimal results. (37:10)Dr. Lock talks about future research plans into high-oleic soybeans and other fatty acids. The panel comments on the yield of high-oleic soybeans and the availability of seed, both conventional and GMO. (48:48)Panelists share their take-home thoughts. (59:15)Please subscribe and share with your industry friends to invite more people to join us at the Real Science Exchange virtual pub table.  If you want one of our Real Science Exchange t-shirts, screenshot your rating, review, or subscription, and email a picture to anh.marketing@balchem.com. Include your size and mailing address, and we'll mail you a shirt.

In this episode of The Dairy Podcast Show, Jennifer Weber from Afimilk discusses how data-driven technology is transforming dairy management. She explains how feed efficiency algorithms and cow-level data are transforming breeding, replacement strategies, and sustainability strategies on farms. Discover how digital tools are redefining productivity and profitability in the dairy industry. Listen now on all major platforms!"We can confidently say now in the general market, we were able to get a 94% accuracy on individualized dry matter intake."Meet the guest: Jennifer Weber is the Director of Customer Success and Midwest Commercial Manager for Afimilk USA. She leads operations and customer success initiatives across North America. With a dual background in Dairy Science and Biochemistry from the University of Wisconsin–Platteville, Jennifer brings years of experience in integrating technology into dairy operations. Liked this one? Don't stop now — Here's what we think you'll love!What you'll learn:(00:00) Highlight(01:41) Introduction(05:13) Feed efficiency innovation(07:31) Data and sensors(09:12) On-farm applications(11:41) Long-term strategy(18:06) Future technologies(01:41) Final three questionsThe Dairy Podcast Show is trusted and supported by innovative companies like:* Afimilk* Evonik* Priority IAC* Lallemand* Adisseo- Berg + Schmidt- SmaXtec- dsm-firmenich- ICC- Protekta- AHV- Natural Biologics